DVL Stock Overview Acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Alliance Pharma plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Alliance Pharma Historical stock prices Current Share Price UK£0.69 52 Week High UK£0.85 52 Week Low UK£0.30 Beta 0.62 1 Month Change 24.11% 3 Month Change 39.56% 1 Year Change 58.68% 3 Year Change -43.03% 5 Year Change -28.94% Change since IPO -37.22%
Recent News & Updates
An undisclosed funds, managed by DBAY Advisors Limited, An undisclosed funds, managed by Baring Asset Management Limited, Edmond De Rothschild Equity Strategies IV Fund, a fund managed by Edmond de Rothschild Private Equity Management Ltd. reached an agreement to acquire remaining 72.05% stake in Alliance Pharma plc (AIM:APH) from Andrew Franklin and Richard Jones for approximately £250 million. Jan 11 An undisclosed funds, managed by DBAY Advisors Limited, An undisclosed funds, managed by Baring Asset Management Limited, Edmond De Rothschild Equity Strategies IV Fund, a fund managed by Edmond de Rothschild Private Equity Management Ltd. reached an agreement to acquire remaining 72.05% stake in Alliance Pharma plc (AIM:APH) from Andrew Franklin and Richard Jones for approximately £250 million. Jan 10
New minor risk - Share price stability Jan 02
High number of new directors Dec 30
First half 2024 earnings released: EPS: UK£0.009 (vs UK£0.009 in 1H 2023) Oct 02
Alliance Pharma plc to Report First Half, 2024 Results on Sep 30, 2024 Sep 12 See more updates
An undisclosed funds, managed by DBAY Advisors Limited, An undisclosed funds, managed by Baring Asset Management Limited, Edmond De Rothschild Equity Strategies IV Fund, a fund managed by Edmond de Rothschild Private Equity Management Ltd. reached an agreement to acquire remaining 72.05% stake in Alliance Pharma plc (AIM:APH) from Andrew Franklin and Richard Jones for approximately £250 million. Jan 11 An undisclosed funds, managed by DBAY Advisors Limited, An undisclosed funds, managed by Baring Asset Management Limited, Edmond De Rothschild Equity Strategies IV Fund, a fund managed by Edmond de Rothschild Private Equity Management Ltd. reached an agreement to acquire remaining 72.05% stake in Alliance Pharma plc (AIM:APH) from Andrew Franklin and Richard Jones for approximately £250 million. Jan 10
New minor risk - Share price stability Jan 02
High number of new directors Dec 30
First half 2024 earnings released: EPS: UK£0.009 (vs UK£0.009 in 1H 2023) Oct 02
Alliance Pharma plc to Report First Half, 2024 Results on Sep 30, 2024 Sep 12
Alliance Pharma plc Announces Jeyan Heper to Leave the Business as Chief Operating Officer, Effective 31 August 2024 Jul 23
Alliance Pharma plc, Annual General Meeting, Jul 29, 2024 Jun 20
Full year 2023 earnings released: UK£0.061 loss per share (vs UK£0.002 profit in FY 2022) Jun 20
Alliance Pharma plc Provides Preliminary Results for the Year Ended 31 December 2023 Jun 20
Alliance Pharma plc to Report Fiscal Year 2023 Results on Jun 19, 2024 Jun 19
Amberen, Brand of Alliance Pharma plc, Announces Launch of Amberen ENERGY MOOD SLEEP Gummies Jun 01
Amberen, Brand of Alliance Pharma plc, Announces Launch of Amberen ENERGY MOOD SLEEP Gummies May 31
Alliance Pharma plc Announces CEO Changes May 09
Alliance Pharma plc to Report Fiscal Year 2023 Results on Apr 09, 2024 Mar 04
Alliance Pharma plc Announces Board Changes Feb 05
High number of new directors Dec 01
Alliance Pharma plc Announces Appointment of Non-Executive Directors Nov 07
New minor risk - Share price stability Nov 03
Alliance Pharma plc Provides Earnings Guidance for the Second Half of 2023 Sep 27
Alliance Pharma plc Provides Earnings Guidance for the Second Half of 2023 Sep 26
Alliance Pharma plc to Report First Half, 2023 Results on Sep 26, 2023 Aug 10
Upcoming dividend of UK£0.012 per share at 3.1% yield Jun 15
Full year 2022 earnings released: EPS: UK£0.002 (vs UK£0.014 in FY 2021) Mar 22 Alliance Pharma plc Appoints Martin Sutherland as Non-Executive Director
Alliance Pharma plc to Report Fiscal Year 2022 Final Results on Mar 21, 2023 Jan 17 Alliance Pharma plc Announces Executive Changes
Logistics Development Group plc acquired a 2.38% stake in Alliance Pharma plc for £5.9 million. Dec 24 Alliance Pharma plc Announces CEO Changes
First half 2022 earnings released: EPS: UK£0.024 (vs UK£0.015 in 1H 2021) Sep 21 Alliance Pharma plc Announces Revenue Guidance for Second Half of 2022
Investor sentiment deteriorated over the past week Jul 22
Upcoming dividend of UK£0.011 per share Jun 02 Alliance Pharma plc Announces Directorate Changes
Alliance Pharma plc to Report First Half, 2022 Results on Sep 20, 2022 May 12
Alliance Pharma plc, Annual General Meeting, May 18, 2022 Apr 07
Alliance Pharma plc, Annual General Meeting, May 18, 2022 Apr 06
Insufficient new directors Feb 02
First half 2021 earnings released: EPS UK£0.015 (vs UK£0.003 loss in 1H 2020) Sep 23
Upcoming dividend of UK£0.011 per share Jun 03
Alliance Pharma plc Provides Earnings Guidance for the Full Year of 2021 May 19
Independent Non-Executive Director has left the company May 04
Full year 2020 earnings released: EPS UK£0.015 (vs UK£0.048 in FY 2019) Mar 25
New 90-day high: €0.98 Jan 20 Alliance Pharma plc, Annual General Meeting, May 19, 2021
Alliance Pharma plc (AIM:APH) acquired Biogix, Inc. for $110 million. Dec 30
New 90-day high: €0.84 Dec 10
New 90-day high: €0.83 Nov 05
First half earnings released Sep 23
New 90-day low - €0.80 Jul 28
Alliance Pharma plc to Report First Half, 2020 Results on Sep 22, 2020 Jul 21 Shareholder Returns DVL DE Pharmaceuticals DE Market 7D 33.7% 2.5% 1.3% 1Y 58.7% -15.2% 9.0%
See full shareholder returns
Return vs Market: DVL exceeded the German Market which returned 9% over the past year.
Price Volatility Is DVL's price volatile compared to industry and market? DVL volatility DVL Average Weekly Movement 12.6% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: DVL's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: DVL's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Alliance Pharma plc acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. It provides its products under the Aloclair, Anbesol, Asthon & Parsons, Forceval, Hydromol, Kelo-Cote, MacuShield, Vamousse, Nizoral, and Amberen brand names. The company was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.
Show more Alliance Pharma plc Fundamentals Summary How do Alliance Pharma's earnings and revenue compare to its market cap? DVL fundamental statistics Market cap €393.59m Earnings (TTM ) -€40.02m Revenue (TTM ) €218.25m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) DVL income statement (TTM ) Revenue UK£183.15m Cost of Revenue UK£74.33m Gross Profit UK£108.82m Other Expenses UK£142.40m Earnings -UK£33.58m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.062 Gross Margin 59.42% Net Profit Margin -18.34% Debt/Equity Ratio 46.0%
How did DVL perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/11 08:21 End of Day Share Price 2025/01/10 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Alliance Pharma plc is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Samuel England Berenberg Julie Simmonds Canaccord Genuity Mark Brewer Cavendish
Show 13 more analysts 
